BriaCell Therapeutics Corp.
BCTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001610820
No open-market purchases or sales by BriaCell Therapeutics Corp. insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $1.58M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in BriaCell Therapeutics Corp. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- −12 vs. Q4 2024
- Shares held
- 26.0K
- −648.8K (−96.1%) vs. Q4 2024
- Total value
- $94.1K
- −$284.9K (−75.2%) vs. Q4 2024
- New holders
- 3
- 0 more added
- Sold out
- 15
- 11 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BCTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 19 | $1.58M |
| Q1 2026 | 16 | $1.62M |
| Q4 2025 | 13 | $69.2K |
| Q3 2025 | 13 | $136.5K |
| Q2 2025 | 16 | $181.1K |
| Q1 2025 | 14 | $94.1K |
| Q4 2024 | 26 | $379.1K |
| Q3 2024 | 22 | $538.1K |
| Q2 2024 | 20 | $452.0K |
| Q1 2024 | 20 | $6.38M |
| Q4 2023 | 26 | $14.6M |
| Q3 2023 | 21 | $17.0M |
| Q2 2023 | 21 | $17.9M |
| Q1 2023 | 21 | $19.4M |
| Q4 2022 | 21 | $12.3M |
| Q3 2022 | 22 | $14.3M |
| Q2 2022 | 22 | $17.0M |
| Q1 2022 | 18 | $33.5M |
| Q4 2021 | 20 | $10.9M |
| Q3 2021 | 21 | $4.77M |
| Q2 2021 | 24 | $20.3M |
| Q1 2021 | 10 | $1.45M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding BriaCell Therapeutics Corp.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 19,066 | $69.6K | 0.00% | −20,540−51.9% | Reduced |
| Group One Trading, L.P. | 2,925 | $10.8K | 0.00% | −64,960−95.7% | Reduced |
| Royal Bank of Canada | 1,000 | $4.00K | 0.00% | +1,000 | New |
| National Bank of Canada | 944 | $2.86K | 0.00% | −6,776−87.8% | Reduced |
| SBI Securities Co., Ltd. | 600 | $2.19K | 0.00% | −4,400−88.0% | Reduced |
| Morgan Stanley | 593 | $2.16K | 0.00% | −1,065−64.2% | Reduced |
| Concord Wealth Partners | 333 | $1.22K | 0.00% | −4,667−93.3% | Reduced |
| TD Waterhouse Canada Inc. | 190 | $659 | 0.00% | −2,660−93.3% | Reduced |
| Advisor Group Holdings, Inc. | 67 | $244 | 0.00% | −953−93.4% | Reduced |
| HHM Wealth Advisors, LLC | 66 | $241 | 0.00% | −934−93.4% | Reduced |
| Wells Fargo & Company | 32 | $116 | 0.00% | −258−89.0% | Reduced |
| Tower Research Capital LLC (TRC) | 10 | $37 | 0.00% | +10 | New |
| BlackRock, Inc. | 1 | $4 | 0.00% | +1 | New |
| FNY Investment Advisers, LLC | 200 | $0 | 0.00% | −1,300−86.7% | Reduced |
| Vontobel Holding Ltd. | 0 | $0 | 0.00% | −110,000−100.0% | Sold out |
| Cantor Fitzgerald, L. P. | 0 | $0 | 0.00% | −56,000−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −50,609−100.0% | Sold out |
| Onyx Bridge Wealth Group LLC | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −48,663−100.0% | Sold out |
| LPL Financial LLC | 0 | $0 | 0.00% | −39,259−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −37,989−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −35,041−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −29,657−100.0% | Sold out |
| HighTower Advisors, LLC | 0 | $0 | 0.00% | −24,628−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −19,409−100.0% | Sold out |
| United Capital Management of KS, Inc. | 0 | $0 | 0.00% | −15,250−100.0% | Sold out |
| Wolverine Trading, LLC | 0 | $0 | 0.00% | −13,538−100.0% | Sold out |
| Cambridge Investment Research Advisors, Inc. | 0 | $0 | 0.00% | −11,200−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −15−100.0% | Sold out |